Scleroderma, Diffuse
3
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Cell Therapy
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Novartisrapcabtagene autoleucel
InventivaIVA337
Bristol Myers SquibbAVID200
Clinical Trials (3)
Total enrollment: 105 patients across 3 trials
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Start: Oct 2024Est. completion: Aug 203296 patients
Phase 2Recruiting
Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
Start: Oct 2015Est. completion: Oct 2018
Phase 2Completed
Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis
Start: Jan 2019Est. completion: Jun 20209 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 105 patients
3 companies competing in this space